The dietary supplements glucosamine and chondroitin sulfate, together or alone, appeared to fare no better than placebo in slowing loss of cartilage in osteoarthritis of the knee, researchers from the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) team report in the October issue of Arthritis & Rheumatism. Interpreting the study results is complicated, however, because participants taking placebo had a smaller loss of cartilage, or joint space width, than predicted. Loss of cartilage, the slippery material that cushions the joints, is a hallmark of osteoarthritis and its loss is typically measured as a reduction in joint space width—the distance between the ends of bones in a joint as seen on an X-ray.
“While these results are of interest, we cannot draw definitive conclusions about the utility of glucosamine or chondroitin in reducing joint space width loss, in part because the placebo group fared better than anticipated based on prior research results,” said Josephine P. Briggs, M.D., director of the National Center for Complementary and Alternative Medicine, at the National Institutes of Health (NIH), one of the study’s funders. “The results of the study provide interesting insights for future research.”
Source: http://nccam.nih.gov/news/2008/092908.htm?nav=rss
chemical screening DPP-4 Peptidase-4
Related posts:
- Study Shows Cranberry Juice Cocktail Is No Better Than Placebo at Preventing Recurrent UTIs
- Mouse Study Shows Green Tea Polyphenols May Repair DNA Damage Caused by UV Radiation
- Significant Advances in Dietary Supplement Research Released in Annual Bibliography (2005)
- FDA Alert – Vialipro Dietary Supplement Recalled: Undeclared Drug Ingredient
- Nutrition Express Voluntarily Recalls Protein Supplements Because of Possible Health Risk